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SUMMARY
SETTING—In the Philippines, programmatic treatment of drug-resistant tuberculosis (TB) was 
initiated by the Tropical Disease Foundation in 1999 and transitioned to the National TB Program 
in 2006.
OBJECTIVE—To determine patient and socio-demographic characteristics associated with 
default, and the impact of patient support measures on default.
DESIGN—Retrospective cohort analysis of 583 MDR-TB patients treated from 1999 to 2006.
RESULTS—A total of 88 (15%) patients defaulted from treatment. The median follow-up time 
for patients who defaulted was 289 days (range 1–846). In multivariate analysis adjusted for age, 
sex and previous TB treatment, receiving a greater number of treatment drugs (≥5 vs. 2–3 drugs, 
HR 7.2, 95%CI 3.3–16.0, P < 0.001) was significantly associated with an increased risk of default, 
while decentralization reduced the risk of default (HR 0.3, 95%CI 0.2–0.7, P < 0.001).
CONCLUSION—Improving access to treatment for MDR-TB through decentralization of care to 
centers near the patient’s residence reduced the risk of default. Further research is needed to 
evaluate the feasibility, impact and cost-effectiveness of decentralized care models for MDR-TB 
treatment.
Keywords
drug-resistant tuberculosis; treatment adherence; patient incentives; risk factors; program 
interventions
MULTIDRUG-RESISTANT tuberculosis (MDR-TB) is a global problem, with an estimated 
440 000 new cases and 150 000 deaths in 2008.1 In the Philippines, approximately 5000 
new patients with MDR-TB occur annually, representing about 4% of all new and 21% of 
retreatment cases.2 Treatment for MDR-TB is complex, involving extended treatment with 
toxic and less effective second-line drugs. Although most MDR-TB patients can be cured, 
many default, defined as missing at least 2 consecutive months of treatment during 
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treatment.3 Patients who default or fail treatment are at increased risk for amplified drug 
resistance, leaving few treatment options. These patients are also prone to increased 
morbidity and mortality from TB, and contribute to transmission of drug-resistant TB in the 
community.
In 2000, the Tropical Disease Foundation (TDF), a non-government organization (NGO) in 
collaboration with the Department of Health (DOH), initiated a program to treat patients 
with MDR-TB, based at the Makati Medical Center (MMC) in Metro Manila, capital of the 
Philippines. During the first 3 years, default rates were high, averaging 11.4%.4 In response, 
starting in 2003, TDF implemented several measures to increase treatment adherence. 
Support included provision of food baskets, housing and transportation allowances, ancillary 
drugs to manage adverse events and hospitalization support when necessary. A clinic staff 
member was assigned to monitor patients for treatment interruptions and conduct home 
visits to optimize treatment adherence. Patient care was decentralized to community 
facilities, including faith-based organizations, public health centers and NGOs, once a 
patient had an initial conversion to a negative sputum culture.
In this study, we evaluated the association between patients’ socio-demographic and clinical 
characteristics and the impact of programmatic patient support measures on risk for 
treatment default among patients treated for MDR-TB between 1999 and 2006.
MATERIALS AND METHODS
Population and program description
The present study was conducted in the three MDR-TB treatment centers established by 
TDF in Metro Manila. The first center was a small clinic at the Makati Medical Center, a 
tertiary care hospital. Patient data were reviewed individually and a Category IV treatment 
regimen, based on drug resistance profile and treatment history, was determined by an 
expert committee of MDR-TB clinicians. With the exception of critically ill patients, review 
of current drug susceptibility testing (DST) results was required before treatment initiation. 
Prescribed regimens included at least four drugs, including a second-line injectable drug in 
the first 6 months or until the patient was culture-negative for 4 months (intensive phase), a 
fluoroquinolone that the patient had not previously received and at least two of the Group 4 
drugs (cycloserine, prothionamide, para-aminosalicylic acid). Dosages were based on 
guidelines initially provided by Partners in Health5 and later by the World Health 
Organization (WHO).6
All patients were given directly observed treatment (DOT) at an out-patient clinic 6 days a 
week. All doses were recorded on a patient treatment card. Patients who lived outside Metro 
Manila or more than 10 km from the treatment center were asked to transfer to a residence 
within 5 km of the center. Treatment was monitored by monthly smears throughout therapy, 
and monthly sputum cultures during the intensive phase and every other month during the 
last 12 months of treatment. Smears, cultures and DST were performed by the TDF 
laboratory, which was quality assured by the Korean Institute of Tuberculosis. Final 
treatment outcomes were determined by consensus after review among a committee of 
MDR-TB clinicians using standard WHO definitions.3,6
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The first patients enrolled were those who failed a retreatment regimen in the TDF clinic and 
were diagnosed with MDR-TB. Initial patients were provided with free first- and second-
line anti-tuberculosis drugs with DOT support; no other form of support could be offered 
due to limited funds. The default rate for the first cohort of 117 MDR-TB patients treated 
during 1999–2003 was 9%.7 In 2004 and 2005, the program expanded to include two 
additional centers in nearby Quezon City with housing facilities, out-patient services and 
patient support measures, including food baskets, housing and transportation allowances, 
and free ancillary drugs for the management of adverse drug reactions (ADRs). Support 
measures or enablers were given on an as-needed basis as determined by the facility social 
worker. The additional centers facilitated access to physicians and nurses, and staffing at 
each center was increased to include a social worker, a pharmacist, a psychiatrist and a 
psychologist. In 2006, the TDF-initiated program started integration with the Philippines 
Department of Health National TB Program.
Study design
All patients enrolled in the MDR-TB treatment program from 1999 to 2006 who had a final 
treatment outcome were included in the analysis. Individual patient and programmatic 
factors were abstracted from patient medical charts, social work and fiscal records. 
Treatment outcomes were abstracted from patient charts or records of the case management 
committee. Pharmacy records were abstracted to determine ancillary drugs prescribed to 
patients during treatment.
Exposure variables
Baseline patient socio-demographic and clinical information abstracted included age, sex, 
income, marital status, body mass index (BMI), history of smoking, alcohol and substance 
abuse, the number of previous courses of anti-tuberculosis treatment, duration of illness, 
history of TB or MDR-TB exposure, history of default from previous anti-tuberculosis 
treatment and extent of disease. Patient charts were reviewed to establish whether the patient 
had comorbidities, including diabetes, cancer, lung disease, seizures or human 
immunodeficiency virus infection. Treatment characteristics, including baseline DST results, 
treatment drugs, treatment start and stop dates, treatment interruptions in the intensive and 
continuation phase, DOT adherence and ADRs were noted. ADRs were defined as any 
documented event reported by the patient to the clinician during the course of treatment. 
Information about programmatic factors, including treatment delay, and the provision of 
food baskets, housing and transportation allowance, hospitalization support and ancillary 
drugs was abstracted.
All information was recorded on standardized forms designed for the study. All data were 
verified by a member of the research staff independent from the data abstractor.
Definitions used for data analysis
Patients were categorized as defaulters (those who missed at least 2 consecutive months of 
treatment) or non-defaulters (cured, treatment completed, death, failed) based on standard 
WHO definitions.3 Duration of illness was defined as the duration of symptoms reported on 
the screening form. Waiting time to diagnosis was defined as the date DST results were 
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reported to the clinic minus the sputum collection date. Waiting time to start of treatment 
was defined as the date treatment started minus the date of initial screening. Waiting time 
from diagnosis to treatment was defined as treatment start date minus the date the DST was 
released to the clinician. ADRs were considered uncontrolled if the same reaction was 
reported at least three times prior to treatment outcome, if it was reported continuously for at 
least 2 weeks or if it required hospitalization. Treatment interruption was defined as missing 
more than 4 consecutive days of treatment. Decentralization was defined as the transfer of 
care from a centralized MDR-TB treatment center to a community DOTS facility. Number 
of drugs used was defined as the number of drugs at the last day of treatment intake. Patients 
were treated for at least 18 months after stable culture conversion to negative. For this 
analysis, the intensive phase of treatment was defined as the initial period of treatment until 
four consecutive cultures were negative. If the patient had frequent treatment interruptions, 
the end of the intensive phase was defined as completion of 156 doses following the first 
month of negative culture. The continuation phase was defined as the period after the 
intensive phase lasting for at least 12 months, or until 312 doses were completed or until 18 
consecutive culture-negative months were reached.
For this analysis we defined the pre-support phase as the period from 1999 to 1 August 
2003, when the only support provided to patients was free anti-tuberculosis drugs. Support 
phase refers to the period from 1 August 2003 to 2006, when the program was enhanced 
with additional staffing, decentralization and patient incentives as described above.
Data analysis
The distribution of patient and program factors among defaulters was compared to non-
defaulters using the χ2 test. Time from initiation of treatment to treatment outcome (default 
or non-default) was calculated. Cox proportional hazards analysis was used to determine the 
association between patient and program characteristics and default. All variables that 
occurred at a specific time after treatment initiation were considered as time-varying. 
Unadjusted models were fit using each risk factor of interest as the only variable in the 
model, and variables with P < 0.20 were considered for the multivariate model. Tests for 
collinearity were performed to identify correlation between factors. The final model 
included age and factors identified as significantly associated with treatment default based 
on an alpha level of 0.05. A stratified analysis was also conducted to examine factors 
associated with default in the pre-support and support phases of the program, with patient 
cohorts (strata) determined by the time of treatment initiation. All data were analyzed using 
Stata 9.0 (Stata Corp, College Station, TX, USA).
Ethical review
The study was approved by the TDF Institutional Review Board.
RESULTS
A total of 610 patients were treated for MDR-TB by our centers from 1999 to 2006. Medical 
records and treatment outcomes were available for 583 treatment episodes for 577 patients 
(six patients had two episodes); of these, 88 (15%) defaulted from treatment. The median 
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follow-up time for all patients was 584 days, while the median follow-up time for patients 
who defaulted was 289 days (range 1–846). The majority (n = 55, 63%) of patients who 
defaulted from treatment did so during the intensive phase of treatment (Figure). The 
average age was 39 years (range 6–80), and the majority were male (Table 1). Most patients 
were college graduates (52%), and most were also unemployed (66%). Almost half (49%) of 
the patients were underweight (BMI < 18.5 kg/m2). A history of alcohol abuse was recorded 
for 63%; 98% of the patients had a history of prior anti-tuberculosis treatment, with 86% 
having had at least two previous courses of treatment (Table 2). The majority of the patients 
had pulmonary TB, with bilateral lung involvement. Of 194 patients tested for susceptibility 
to both first- and second-line drugs (ofloxacin and kanamycin) with available results, 22 
(11%) had extensively drug-resistant TB. At the time of presentation, almost half of the 
patients reported having TB symptoms for more than 1 year, and 48% had a waiting time of 
6 months to more than 1 year from the time of screening to treatment initiation. Most 
patients (53%) were treated with a four-drug regimen, and most defaulters were treated with 
five or more drugs. Patients who defaulted were more likely to have treatment interruptions 
during both the intensive and continuation phases.
Patients whose treatment was decentralized after culture conversion were less likely to 
default than those whose treatment was continued at one of the central TDF MDR-TB 
treatment centers (Table 3). None of the other patient support measures were significantly 
associated with default. The overall proportion of patients who defaulted on treatment did 
not differ during the pre-support and support phases.
In multivariate analysis adjusted for age, sex and previous anti-tuberculosis treatment, 
receiving a greater number of drugs (≥5 vs. 2–3 drugs, hazard ratio [HR] 7.2, 95% 
confidence interval [CI] 3.3–16.0, P < 0.001) was significantly associated with increased 
risk for default, while decentralization reduced the risk of default (HR 0.3, 95%CI 0.2–0.7, 
P < 0.001, Table 4). These results were similar when the analysis was restricted to the cohort 
of patients who initiated treatment during the support phase.
DISCUSSION
Our study confirms other reports8–11 that default during treatment is a persistent problem for 
MDR-TB programs. Our treatment cohort from 1999 to 2006 had a 15% default rate, similar 
to rates experienced in other settings, including Korea (39%8 and 28.9%),9 Latvia (13%),10 
and Peru (11%6 and 10%).11 The MDR-TB program in the Philippines has implemented 
interventions aimed at reducing default, including transportation to DOT treatment centers, 
housing allowance, food baskets and decentralization of treatment to facilities near the 
patient’s residence. Reducing default rates will improve treatment success rates and reduce 
the risk of additional acquired drug resistance and the spread of drug-resistant strains in the 
community.
In this retrospective cohort study among patients with MDR-TB in a high TB burden 
country, patients receiving treatment regimens containing at least five drugs had an 
increased risk for treatment default, and decentralization of MDR-TB treatment to DOTS 
treatment facilities near the patient’s residence was associated with a 70% reduced risk for 
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default. The provision of housing or transport allowances or food baskets was not associated 
with reduced default.
MDR-TB treatment programs have employed several service models since the WHO DOTS-
Plus strategy was started.7 Most countries have adopted an approach that involves 
hospitalization for the initial phase of treatment, aiming to protect the greater community 
from ongoing transmission of drug-resistant TB strains. However, it is important to balance 
the need to protect the public with patient rights and autonomy. In the Philippines, treatment 
for MDR-TB is centralized, and the individual is therefore often required to move away 
from home to access treatment. When a patient is no longer sputum culture-positive, care is 
decentralized to a local health center near the patient’s residence after health care workers in 
the center have been trained to administer and monitor treatment with second-line drugs. 
Studies in other countries have demonstrated that decentralized or community-based models 
of MDR-TB treatment promote favorable patient outcomes, and our findings provide further 
evidence in support of this approach.12,13 Furthermore, a recent review on the cost-
effectiveness of MDR-TB treatment showed that the out-patient care model was more cost-
effective than that for in-patients.14
While decentralization was associated with a lower risk of default, 88 patients still defaulted 
during treatment. Patients default during treatment for multiple reasons, including 
competing health priorities associated with comorbidities,15,16 financial and work 
constraints, and lack of social support.11 A previous study conducted among 240 patients in 
the TDF MDR-TB treatment program from 2003 to 2005 identified that patients who missed 
more than 20% of treatment days, weighed <47 kg, or had TB strains resistant to second-line 
drugs were more likely to default.17
Our study has several limitations. As this study was retrospective, we were unable to assess 
reasons why patients interrupted treatment or defaulted, and we had limited information on 
programmatic factors. The data for this study were abstracted from medical charts that were 
not standardized or intended for research, and data on some variables were missing for some 
patients. Patients who were decentralized had to take their treatment continually for the first 
6 months to establish culture conversion and be eligible for decentralization, potentially 
introducing a survival bias. However, this potential bias was minimized by considering 
decentralization as a time-varying covariate in the analysis. During the support phase, only 
patients considered in need of additional treatment support were provided with program 
incentives. Our inability to identify an association between transport, housing and other 
support measures and default may have been due to a pre-selection of patients at greater risk 
for poor outcomes. Patients who had a greater drug burden during treatment were also 
identified as having a greater risk of default. However, the drug burden was classified 
according to the number of drugs received at the last dose of treatment; if patients were also 
more likely to default during the intensive phase, this could potentially inflate the 
association between the drug burden and default risk. It is also possible that these patients 
were provided with more drugs due to a history of poor adherence or because they had a TB 
strain resistant to several first-line drugs, both risk factors for treatment default and poor 
outcomes. Moreover, there may have been a competing risk of death in the 2–3 drug referent 
group. The increased risk of default among patients who received ≥5 drugs could be due, in 
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part, to increased risk of death in patients receiving 2–3 drugs, a substandard regimen by 
global recommendations. Despite these limitations, this study provides a comprehensive 
assessment of patient, disease, treatment and program factors for a cohort of over 500 
patients treated for MDR-TB. We were able to assess the impact of several patient treatment 
support interventions on treatment default, which will be used to inform our treatment 
program and others on the best use of limited resources.
In conclusion, decentralization of treatment to facilities near a patient’s residence reduced 
default during treatment for MDR-TB in a high-burden country. Additional research is 
needed to further identify programmatic and patient factors that may contribute to risk of 
default. As the global burden of MDR-TB continues to expand and exceeds the capacity of 
countries to hospitalize or provide centralized treatment, it will be critical to assess the 
impact of different strategies on treatment outcomes and community transmission, and the 
cost-effectiveness of implementing these programs.
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Number of patients who defaulted from treatment during the intensive and continuation 
phases of MDR-TB treatment, by duration of MDR-TB treatment follow-up time prior to 
default, in months (n = 88). MDR-TB = multidrug-resistant tuberculosis.
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n (%) P value*
Age group, years
 1–24 62 (13) 14 (16) 73 (13)
 25–44 279 (56) 45 (51) 324 (56)
 45–64 145 (29) 27 (31) 172 (30)
 ≥65 9 (2) 2 (2) 11 (2) 0.76
Male sex 293 (59) 58 (66) 351 (60) 0.24
Highest level of education
 <High school 36 (13) 6 (13) 42 (13)
 High school 95 (33) 13 (29) 108 (33)
 College or graduate 153 (54) 26 (58) 179 (54) 0.83
Married 294 (60) 58 (66) 352 (60) 0.26
Unemployed 316 (67) 54 (62) 370 (66) 0.41
Income ≤5000 Ph pesos
†
/month
109 (22) 22 (25) 131 (22) 0.54
Underweight (BMI <18.5 kg/m2) 212 (49) 37 (49) 249 (49) 0.98
History of smoking 198 (40) 42 (48) 240 (41) 0.18
History of alcohol use 207 (42) 45 (63) 252 (43) 0.10
History of substance abuse 60 (12) 15 (17) 75 (13) 0.20
Diabetes mellitus 129 (26) 15 (17) 144 (25) 0.07
Lung disease 63 (13) 5 (6) 68 (12) 0.06
BMI = body mass index.
*
Using χ2 test comparing defaulters and non-defaulters.
†
1 USD = 42.67 Ph pesos.
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n (%) P value*
Number of previous anti-tuberculosis treatment episodes
 None 7 (1) 5 (6) 12 (2)
 1 60 (12) 8 (9) 68 (12)
 ≥2 428 (86) 75 (85) 503 (86) 0.03
Baseline disease characteristics
 Culture-positive
† 473 (96) 84 (95) 557 (96) 0.90
 Bilateral disease
† 363 (80) 59 (75) 422 (79) 0.29
 Cavitary disease
† 190 (42) 29 (37) 219 (41) 0.37
DST pattern
‡
 First-line drugs only (H, R, Z, E, S) 300 (63) 50 (58) 350 (62) 0.43
 HR + 1 second-line drug class (± other first-line drug;
   not XDR-TB)
154 (79) 32 (84) 186 (80) 0.47
 XDR-TB (HR + second-line injection + FQ) 18 (11) 4 (15) 22 (11) 0.49
Diagnosis, treatment, clinical course
 Duration of current illness at time of screening
 <2 weeks 10 (2) 1 (1) 11 (2)
 2 weeks–1 month 43 (9) 6 (7) 49 (9)
 >1 month–1 year 184 (40) 32 (40) 216 (40)
 >1 year 223 (48) 42 (52) 265 (49) 0.86
Total waiting time from screening to treatment start
 <1 month 74 (15) 5 (6) 79 (14)
 1–5 months 188 (38) 33 (38) 221 (38)
 6 months–1 year 176 (36) 41 (47) 217 (37)
 >1 year 57 (12) 9 (10) 66 (11) 0.06
Total number of drugs used during treatment
 2–3 133 (27) 9 (10) 142 (24)
 4 285 (58) 26 (30) 311 (53)
 ≥5 77 (16) 53 (60) 130 (22) <0.001
Uncontrolled ADRs 270 (55) 43 (49) 313 (54) 0.35
Hospitalized while on treatment 109 (22) 17 (19) 126 (22) 0.55
Treatment interruption (>4 missed doses) during
  intensive phase
143 (29) 58 (66) 201 (35) <0.001
Treatment interruption (>4 missed doses) during
  continuation phase
253 (57) 30 (73) 283 (58) 0.04
*
Using χ2 test comparing defaulters and non-defaulters.
†
Among pulmonary TB patients (n = 569).
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‡
Of those patients with DST results available: n = 565 for first-line drugs; n = 233 for first + at least 1 class of second-line drugs; n = 194 for XDR-
TB. DST = drug susceptibility testing; H = isoniazid; R = rifampin; Z = pyrazinamide; E = ethambutol; S = streptomycin; XDR-TB = extensively 
drug-resistant tuberculosis; FQ = fluoroquinolone; ADR = adverse drug reaction.
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n (%) P value*
Transportation
 allowance 80 (16) 11 (13) 91 (16) 0.38
Housing allowance 15 (4) 2 (3) 17 (3) 0.67
Food baskets 231 (47) 34 (39) 265 (45) 0.16
Ancillary drugs 71 (14) 8 (9) 79 (14) 0.19
Hospitalization
 support (if
 hospitalized) 22 (4) 1 (1) 23 (4) 0.14
Decentralization 158 (32) 9 (10) 167 (29) <0.001
*
Using χ2 test comparing defaulters and non-defaulters.
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Table 4
Association between patient and program characteristics and risk for treatment default among patients treated 
for multidrug-resistant tuberculosis from 1999–2006
Characteristic
Multivariate*
HR (95%CI) P value
Number of drugs used
  during treatment
 2–3 Reference
 4 1.3 (0.6–2.8) 0.51
 ≥5 7.2 (3.3–16.0) <0.001
Decentralization 0.3 (0.2–0.7) 0.006
HR = hazard ratio; CI = confidence interval.
*
Model also adjusted for age, sex and history of previous anti-tuberculosis treatment.
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